SCHEMBL19925907

SCHEMBL19925907

N#CC(C(=O)c1ccccc1F)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.47
CES1 P23141 2/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 5/20 0.43
ALOX15 P16050 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
HPGD P15428 4/20 0.42
LMNA P02545 3/20 0.42
HTT P42858 2/20 0.42
USP2 O75604 1/20 0.42
PTPN1 P18031 1/20 0.40
ERCC5 P28715 1/20 0.40
FEN1 P39748 1/20 0.40
TSHR P16473 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 2/20 0.39
TDP1 Q9NUW8 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29875006 1.00 CES2 (0.47) CES2CES1MEN1KMT2ANPSR1
SCHEMBL7196088 0.88 TSHR (0.47) CES2CES1NPSR1L3MBTL1ALDH1A1
SCHEMBL29000829 0.79 CES2 (0.53) CES2CES1MEN1KMT2ANPSR1
SCHEMBL7202991 0.78 LMNA (0.43) CES2CES1MEN1KMT2ANPSR1
SCHEMBL27670818 0.77 CES2 (0.51) CES2CES1MEN1KMT2ANPSR1
SCHEMBL7202862 0.77 L3MBTL1 (0.55) CES2CES1NPSR1L3MBTL1ALDH1A1
SCHEMBL5505530 0.77 L3MBTL1 (0.61) CES2CES1NPSR1L3MBTL1ALDH1A1
SCHEMBL7196084 0.77 LMNA (0.42) CES2CES1MEN1KMT2ANPSR1
SCHEMBL31468409 0.76 CES2 (0.50) CES2CES1MEN1KMT2AALDH1A1
SCHEMBL8691227 0.76 CES2 (0.50) CES2CES1MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49934-E1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2024-04-23 US disclosed
CN-109890822-B Inhibitors of cellular metabolic processes 安吉奥斯医药品有限公司 2022-08-30 CN disclosed
US-11325914-B1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2022-05-10 US disclosed
US-10800782-B2 Inhibitors of cellular metabolic processes Agios Pharmaceutical, Inc. (US) 2020-10-13 US disclosed
US-20190233424-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES SERVIER PHARMACEUTICALS LLC 2019-08-01 US disclosed
EP-3507290-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES Agios Pharmaceuticals, Inc. (US) 2019-07-10 EP disclosed
US-10329298-B2 Inhibitors of cellular metabolic processes AGIOS PHARMACEUTICALS, INC. (US) 2019-06-25 US disclosed
CN-109890822-A INHIBITORS OF CELLULAR METABOLIC PROCESSES 安吉奥斯医药品有限公司 2019-06-14 CN disclosed
US-20180079753-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES SERVIER PHARMACEUTICALS LLC 2018-03-22 US disclosed
WO-2018045071-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES AGIOS PHARMACEUTICALS, INC. (US) 2018-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329298-B2 Inhibitors of cellular metabolic processes MNAT1, MAT2A, PCK2 CES2 3234/4885CES1 1490/4885MEN1 1624/4885
US-20190233424-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES MNAT1, MAT2A, PCK2 CES2 3234/4885CES1 1490/4885MEN1 1624/4885
US-10800782-B2 Inhibitors of cellular metabolic processes MNAT1, MAT2A, PCK2 CES2 3234/4885CES1 1490/4885MEN1 1624/4885
US-20180079753-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES MNAT1, MAT2A, PCK2 CES2 3234/4885CES1 1490/4885MEN1 1624/4885
US-11325914-B1 Inhibitors of cellular metabolic processes MNAT1, MAT2A, PCK2 CES2 3234/4885CES1 1490/4885MEN1 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.